Clinical Trial Update: Early DOlutegravir/LAmivudine Switching After Virological Suppression (EDOLAS Study) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating switching to dolutegravir/lamivudine after virological suppression in HIV-1 infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir/Lamivudine (dolutegravir/lamivudine)

Snippet

Sponsor: Societa' Italiana Di Malattie Infettive E Tropicali | Conditions: HIV-1-infection | Phase 3 | Status: UNKNOWN